Mesenchymal Stem Cells Enhance Allogeneic Islet Engraftment in Nonhuman Primates by Berman, Dora M. et al.
Mesenchymal Stem Cells Enhance Allogeneic Islet
Engraftment in Nonhuman Primates
Dora M. Berman,
1,2 Melissa A. Willman,
1 Dongmei Han,
1 Gary Kleiner,
2,3 Norman M. Kenyon,
1,2
Over Cabrera,
1 Julie A. Karl,
4 Roger W. Wiseman,
4 David H. O’Connor,
4,5 Amelia M. Bartholomew,
6
and Norma S. Kenyon
1,2,7,8
OBJECTIVE—To test the graft-promoting effects of mesenchy-
mal stem cells (MSCs) in a cynomolgus monkey model of
islet/bone marrow transplantation.
RESEARCH DESIGN AND METHODS—Cynomolgus MSCs
were obtained from iliac crest aspirate and characterized
through passage 11 for phenotype, gene expression, differen-
tiation potential, and karyotype. Allogeneic donor MSCs were
cotransplanted intraportally with islets on postoperative day
(POD) 0 and intravenously with donor marrow on PODs 5 and
11. Recipients were followed for stabilization of blood glucose
levels, reduction of exogenous insulin requirement (EIR),
C-peptide levels, changes in peripheral blood T regulatory
cells, and chimerism. Destabilization of glycemia and in-
creases in EIR were used as signs of rejection; additional
intravenous MSCs were administered to test the effect on
reversal of rejection.
RESULTS—MSC phenotype and a normal karyotype were ob-
served through passage 11. IL-6, IL-10, vascular endothelial
growth factor, TGF-, hepatocyte growth factor, and galectin-1
gene expression levels varied among donors. MSC treatment
signiﬁcantly enhanced islet engraftment and function at 1 month
posttransplant (n  8), as compared with animals that received
islets without MSCs (n  3). Additional infusions of donor or
third-party MSCs resulted in reversal of rejection episodes and
prolongation of islet function in two animals. Stable islet allograft
function was associated with increased numbers of regulatory
T-cells in peripheral blood.
CONCLUSIONS—MSCs may provide an important approach
for enhancement of islet engraftment, thereby decreasing the
numbers of islets needed to achieve insulin independence. Fur-
thermore, MSCs may serve as a new, safe, and effective antire-
jection therapy. Diabetes 59:2558–2568, 2010
M
ultipotent mesenchymal stem cells (MSCs)
(1,2) can deliver immunomodulatory signals
(3–7) that inhibit allogeneic T-cell responses
through downregulation of the proinﬂamma-
tory cytokines TNF- and IFN- and production of the
regulatory cytokines/molecules IL-10, hepatocyte growth
factor (HGF), TGF-, vascular endothelial growth factor
(VEGF), indoleamine 2,3-dioxygenase, galectin-1, prosta-
glandin E2, nitric oxide, and matrix metalloproteinase-2
and -9 (3,8–12). Inﬂammatory signals, such as IFN-, can
activate and upregulate MSC suppressive activities (9,13).
These cells are able to migrate to sites of injury after
intravenous injection (14,15). Their use in clinical trials
and experimental models is based on their immunomodu-
latory and regenerative properties (1,7,16). Clinically,
MSCs have been observed to enhance donor bone marrow
cell (DBMC) engraftment and chimerism (17,18). There-
fore, cotransplantation of MSCs that secrete immuno-
modulatory cytokines and growth factors might enhance
islet survival and function. In experimental mouse models,
intravenously infused MSCs are capable of migrating to
pancreatic islets (19,20). Systemic infusion of MSCs in
murine models of diabetes was accompanied by delayed
onset of diabetes, improved glycemic levels, reduced
pancreatic insulitis, and pancreatic tissue regeneration
(19,21–25), as well as prevention of autoimmune destruc-
tion of -cells via induction of regulatory T-cells (Tregs)
(26). Cotransplantation of syngeneic MSCs with a marginal
mass of allogeneic islets under the kidney capsule of
streptozotocin (STZ)-induced diabetic mice resulted in
prolonged normoglycemia (11). Cotransplantation of syn-
geneic MSC with a marginal mass of allogeneic islets has
been performed in the omentum (27) and kidney capsule
(28) of STZ-induced diabetic rats, with enhanced islet graft
survival as compared with animals receiving islets alone.
In this study, cynomolgus monkey MSCs were character-
ized and donor MSCs were examined for the ability to
promote intraportal islet engraftment as well as chimerism
in recipients of islet/DBMC transplants. In addition, we
tested the use of donor or third-party MSCs to reverse
episodes of islet allograft rejection.
RESEARCH DESIGN AND METHODS
Donor and recipient cynomolgus monkeys (4 and 2 years of age, respec-
tively) were obtained from Charles River BRF, Inc. (Houston, TX) or Alpha
Genesis, Inc. (Yemassee, SC) and were negative for TB, Herpes B, SRV, SIV,
and STLV-1. Each donor–recipient pair was tissue typed retrospectively and
demonstrated to be fully or partially mismatched for major histocompatibility
complex (MHC) class II alleles identiﬁed using microsatellite analysis as
previously described (29–31). All study transplant protocols were approved
by The Institutional Animal Care and Use Committee of The University of
Miami.
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tation. Diabetes was induced with STZ (1,250 mg/m
2 i.v.) (32) and deﬁned as
fasting C-peptide 0.2 and stimulated C-peptide 0.3 ng/ml in response to a
glucagon challenge undertaken four weeks after STZ (32). Blood glucose
levels were monitored 2–3 times daily via heel stick. Subcutaneous insulin was
administered as needed, on the basis of an individualized sliding scale, to
maintain the following plasma glucose levels: 250–350 for the ﬁrst 2 weeks
after STZ; 175–250 for the third and fourth weeks; and 75–150 mg/dl before
and after transplantation. Using established methods, the donor pancreas was
recovered, islets were isolated and cultured for 39–42 h, and islets were
collected, washed, and counted for transplantation into the liver as previously
described (32). For group 1 (Table 1), islets were infused ﬁrst, followed
immediately by infusion of DBMCs. For group 2 (Table 2), MSCs were added
to the islet preparation 15–20 min before intraportal infusion.
Isolation of donor hematopoietic stem cells. Donor vertebral bodies were
harvested and processed to obtain DBMCs as previously described (33).
DBMCs were depleted of CD11b positive cells using EasySep magnetic cell
separation (Stem Cell Technologies, Vancouver, BC), cryopreserved in cryo-
MACS freezing bags (Miltenyi, Auburn, CA) at a concentration of 500  10
6
cells per bag, and stored until infusion.
Isolation, culture, and expansion of MSCs. Bone marrow aspirates were
harvested from the iliac crest of donor or third-party monkeys and processed
with Ficoll Paque Plus to obtain mononuclear cells. Cells (P0, bone marrow
aspirate) were plated at a density of 5  10
7 cells per 185 cm
2 Nunclon Delta
Solo ﬂask (VWR, West Chester, PA) in culture media consisting of Minimum
Essential Medium Alpha Media (Invitrogen) supplemented with 20% fetal
bovine serum (FBS) (Hyclone, Logan, UT), 1% penicillin-streptomycin (In-
vitrogen), and 1% L-glutamine (Mediatech). Cells were kept in culture at 37°C,
5% CO2, with two media changes weekly. Once cells reached conﬂuency, the
adherent cells were removed using 0.25% Trypsin-EDTA (Invitrogen) (37°C for
5 min). P1 and P2 cells (after ﬁrst and second trypsinization, respectively)
were plated at a concentration of 1  10
6 cells per ﬂask; subsequent passages
were plated at 10
7 cells/ml; cells were cryopreserved in 90% FBS and 10%
dimethlysulfoxide (Sigma).
Characterization of MSCs
Differentiation. Following manufacturer’s instructions (Human Mesenchy-
mal Stem Cell Functional Identiﬁcation Kit,R&DSystems, Minneapolis, MN),
MSCs were characterized for osteogenic and adipogenic differentiation.
Immunomodulatory capacity. P2 MSCs (5  10
4 cells) were allowed to
adhere for 24 h to a U-bottomed 96-well plate (Corning, NY), followed by
addition of responding peripheral blood mononuclear cell (PBMC) (1 
10
5/well) and phytohemaglutinin (PHA) at a ﬁnal concentration of 10 g/well,
in 0.2 ml of culture media. Cultures were incubated at 37°C, 5% CO2 for 5 days,
and T-cell proliferation was determined by addition of [
3H]thymidine (GE
Healthcare) at 1 Ci/well for the last 18 h of culture, harvesting onto ﬁberglass
ﬁlters, and counting.
Karyotyping. Adherent MSCs were treated with Colcemid (0.1 g/ml) for 2 h
prior to cell harvesting. After mitotic arrest, cells were processed in accor-
dance with standard cytogenetics laboratory procedures at the University of
Pittsburgh Cancer Institute Cytogenetics Facility (Pittsburgh, PA).
Gene expression. Total RNA was isolated from MSCs using an RNeasy kit
(Qiagen, Valencia, CA). First-strand cDNA was synthesized using “SuperScript
III First-Strand Synthesis SuperMix for qRT-PCR” kit according to manufac-
turer’s instructions (Invitrogen). Gene expression levels for IL-6, IL-10, HGF,
VEGF, TGF-, and galectin-1 were determined by using Taqman assays
(Applied Biosystems, Foster City, CA) in the LightCycler PCR system (model
1.2, Roche). Taqman assay IDs for the genes are lL6, Hs00985639_m1; IL-10,
Hs00174086_m1; HGF, Hs00300159_m1; VEGF, Rh02621759_m1; TGF-,
TABLE 1
Intraportal cotransplant of allogeneic DBMCs and islets
Group 1
ID no.
MHC class
II match IEQ/kg
Days off
insulin
a
Decrease in
function
b
Days C-peptide
positive/POD
necropsy
Dose
DBMCs
c/
kg  10
9
Dose
CD34/
kg  10
6
POD
chimerism
Peak level
(%) of
chimerism
58y MM 8,000 0 25 326/348 0.64 107 ND ND
93-343 MM 9,724 9 25 45/45 0.48 62.2 1, 5 	2
105-111 MM 11,598 12 21 46/61 0.43 71.5 4 0.37
Animals received induction treatment with four doses of 10 mg/kg thymoglobulin given in the week prior to transplant and four doses of 50
mg/m
2 total of ﬂudarabine. IM rapamycin was initiated 1–5 days prior to intraportal islet/DBMC transplant on POD 0, with a goal of achieving
trough levels of 15–20 ng/ml. DBMCs were debulked with a CD11b bead-based method. Chimerism was measured using 6 class II based
primer and probe sets for donor DNA; the lower limit of detection ranged from 0.03 to 0.1%, depending on the primer probe set.
aNot
necessarily consecutive to islet transplant.
bOn the basis of blood glucose levels, insulin requirement, and/or C-peptide.
cTotal DBMC dose;
DBMCs were given intraportally on POD 0 and intravenously on PODs 5 and 11. ND, not determined; MM, recipient and donor are MHC class
II mismatched.
TABLE 2
Intraportal cotransplant of allogeneic donor MSCs 
 islets
Group 2
ID no.
MHC
class II
match
b IEQ/kg
Days off
insulin
c
Decrease
in
function
d
Days C-peptide
positive/POD
necropsy
Dose
DBMCs
f/
kg  10
9
Dose
CD34/
kg  10
6
POD 0
MSCs/
kg  10
6
IV
MSCs
g/
kg  10
6
POD
chim
h
Peak level
(%) chim
105-131
a haplo 3,000 3 94 354/354 0.17 19.3 1 3.4 38 0.06
26-20
a MM 3,928 0 64 202/202 0.20 23.9 1.6 5.3 UD UD
105-117 haplo 4,581 0 60 60/89 0.31 63.0 1.5 6.2 UD UD
93-108 MM 5,432 5 60 95/137 0.27 57.0 1.2 5.5 31 0.08
CW1H
a haplo 8,185 0 103 251/251 0.11 12.2 1.1 5.1 UD UD
105-71
haplo;
hmz 9,192 89 90 97/97 0.25 35.3 1.2 5 UD UD
35-493
MM;
hmz 10,978 106 106 181/181 0.30 60.4 1.4 5.8 UD UD
105-99 MM 14,000 59 68 75/76
e 0.33 59.8 1.6 6.5 31 0.06
Animals received induction treatment with four doses of 10 mg/kg thymoglobulin given in the week prior to transplant, and four doses of 50
mg/m
2 ﬂudarabine. IM rapamycin were initiated 1–5 days prior to intraportal islet/donor MSC transplant on POD 0, with a goal of achieving
trough levels of 15–20 ng/ml in all animals, except for 105-131, 26-20, and CW1H, in which rapamycin treatment started on POD 14. These
three animals were also treated with anti-CD154. Chimerism was measured using 6 class II based primer and probe sets for donor DNA.
aAnti-CD154 rx.
bMM, recipient and donor are MHC class II mismatched; haplo, MHC class II haploidentical; hmz, homozygous recipient.
cNot
necessarily consecutive to islet transplant.
dOn the basis of blood glucose levels, insulin requirement, and/or C-peptide.
eAnimal expired CMV
positive.
fDBMCs were debulked with a CD11b bead-based method and given intravenously on PODs 4 or 5 and 11.
gMSCs given intravenously
on PODs 5 and 11.
hChimerism, monitored twice per month, determined using 6 class II based primer probe sets for donor DNA; the lower
limit of detection ranged from 0.03 to 0.1%, depending on the primer probe set. UD, undetectable.
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ﬁcation of each sample was performed in a 20-l reaction mixture containing
1X LightCycler FastStart DNA Master Hybridization Probe (Roche Diagnos-
tics, Mannheim, Germany), 1X Taqman assay, 4 mmol/l MgCl2, and 2 l cDNA
sample. PCR ampliﬁcation consisted of 95°C for 10 min, followed by 40 cycles
at 95°C for 10 s and at 60°C for 1 min. DNA fragments from each target gene
(from copy number 10
9 to 10
2) were used to construct the standard curve in
each PCR ampliﬁcation. Results are expressed as the ratio of the copy number
of the target gene to the copy number of 18S.
Flow cytometry analyses
MSC. Cells (10
5) were labeled with conjugated monoclonal antibodies (mAbs)
speciﬁc for CD14, CD29, CD56, CD90, HLA class II (Beckman Coulter,
Fullerton, CA), CD11c, CD34, CD44, CD45, CD73, CD166, HLA class I (BD
PharMingen, San Diego, CA), CD31 (Ebioscience, San Diego, CA), and CD105
(Fitzgerald Industries International, Concord, MA).
Whole blood. EDTA blood (100 l) was labeled with a combination of mAbs
speciﬁc for CD3, CD4, CD45 (BD Pharmingen), CD25 (eBioscience), CD8,
CD11b, CD16, CD20, CD56, CD69, CD127, and HLA class II (Beckman
Coulter); 7AAD was included for viability assessment. Erythrocytes were
lysed using an ImmunoPrep Reagent System and a Q-Prep Workstation
(Beckman Coulter).
Foxp3. Following manufacturer’s instructions, cynomolgus PBMCs were
stained intracellularly for Foxp3, clone PCH101 (eBioscience). All samples
were analyzed on a Coulter Cytomics FC500.
Experimental design, immunosuppressive regimen, and drug levels. Fig.
4A is a schematic of the design used to test the effect of intraportal codelivery
of islets with DBMCs (group 1; Table 1) or with donor MSCs (group 2, Table
2) on chimerism and islet allograft survival. We depleted CD11b positive
vertebral body bone marrow cells to debulk the marrow and remove fragile
myeloid cells. Myeloid cell death results in DNA release, clumping, and
decreased overall cell viability (34). A total of three animals in group 1
received induction therapy consisting of four 10 mg/kg doses of thymoglobulin
and four doses (50 mg/m
2 total) of ﬂudarabine on postoperative days (PODs)
6, 4, 3, and 2. Intramuscular (IM) rapamycin was initiated on POD 2
to achieve and maintain trough levels of 15–20 ng/ml. In this group, we
examined the effect of intraportal codelivery of islets and DBMCs on POD 0,
followed by intravenous infusions of DBMCs on PODs 4 or 5 and 11. The
timing of DBMC infusion was based on previous clinical studies, in which
delayed marrow infusion was found to be optimal in the setting of solid organ
or islet transplantation (35). Group 2 had eight animals that received the same
induction therapy with thymoglobulin and ﬂudarabine. In ﬁve of eight animals,
IM rapamycin was initiated on POD 1 to achieve and maintain trough levels
of 15–20 ng/ml. Rapamycin was delayed (POD 14) for the remaining three
animals (105-131, 26-20, and CW1H), which were also treated with 20 mg/kg
human/mouse chimeric anti-CD154 speciﬁc mAb, derived from the 5c8 clone
(NCRR Nonhuman Primate Reagent Resource), on PODs 1, 0, 3, 10, 18, 28,
and monthly thereafter. The noticeable lack of chimerism observed after the
ﬁrst two animals prompted the addition of parathyroid hormone (PTH) to
augment chimerism in the subsequent six animals (Forteo, 5 g/kg from POD
7o r6 until POD 49) (36). All animals in group 2 were used to examine the
effect of intraportal codelivery of islets and MSCs on POD 0, followed by
intravenous infusions of CD 11b depleted DBMC 
 MSC on PODs 5 and 11.
Chimerism. The levels of donor DNA in a recipient peripheral blood sample
were determined twice per month using LightCycler PCR as previously
described (37). Chimerism results were reported as donor percentages, and
each sample was analyzed in duplicate.
Histopathology. Tissues ﬁxed in 10% neutral buffered formalin and embed-
ded in parafﬁn were sectioned (5 m) and stained with hematoxylin and eosin.
Insulin expression in the islets was assessed by immunohistochemistry using
a guinea pig anti-porcine insulin polyclonal antibody (Dako, Carpinteria, CA)
and a biotinylated donkey anti-guinea pig immunoglobulin (Jackson Immuno-
Research Laboratories, Inc., West Grove, PA), followed by streptavidin-
horseradish peroxidase and revealed by aminoethylcarbazole (Invitrogen,
Carlsbad, CA). For immunoﬂuorescence microscopy, sections were stained
with anti-insulin (AbCam, Cambridge, MA), anti-glucagon (Sigma, St. Louis,
MO), and anti-CD31 (AbCam), anti-CD34 (BioGenex, San Ramon, CA), and
anti-actin (AbCam) for blood vessels followed by Alexa Fluor conjugated
secondary antibodies (Molecular Probes, Carlsbad, CA) as previously
described (38).
Statistics. All data represent means  SEM. A repeated-measures ANOVA
was used to evaluate within-group C-peptide values at different time points
posttransplant, as well as gene expression levels at different MSC passages.
The between-group comparison of C-peptide values at each time point
posttransplant was evaluated using a t test. In all appropriate cases, post hoc
least signiﬁcant difference (LSD) test was used. All analyses were performed
using SPSS 16.0 for Windows (SPSS Inc., Chicago, IL) and P values 0.05 were
considered statistically signiﬁcant.
RESULTS
Isolation, expansion, and characterization of cyno-
molgus monkey MSCs. Vertebral body marrow and iliac
crest aspirate were evaluated as the MSC source, and iliac
crest aspirate was optimal with regards to cell yield. Cells
were characterized to verify absence of cell surface mark-
ers associated with leukocytes (CD11c, 14, 45, 56), endo-
thelial and hematopoietic stem cells (CD31, 34), and HLA
class II and presence of cell surface markers associated
with MSCs in published studies, including CD29, 44, 73, 90,
105, and 166, as well as class I. The percentage of non-MSC
associated markers was highest in the source material,
much lower in P1, and dropped to 1% thereafter, with a
corresponding increase in the percentage of CD105, 29,
and 73 cells to nearly 100% (Fig. 1A and B). Markers
reported on MSCs from other species (CD90, 44, 166), as
well as CD56, were variably positive. Differentiation of
cells to fat and bone veriﬁed MSC identity (Fig. 1C).
Addition of MSCs to cynomolgus mixed lymphocyte reac-
tions resulted in variable suppression of proliferation
(data not shown). In contrast, addition of either autolo-
gous (n  2) or allogeneic (n  13) MSCs to PHA-
stimulated PBMCs signiﬁcantly inhibited proliferation by
85% (Fig. 1D, P  0.009).
We assessed gene expression levels for IL-6, IL-10,
VEGF, TGF-, HGF, and galectin-1 over several passages
of MSC from the same donor, with peripheral blood as a
control; 8 different donors were studied through passage 5
(Fig. 2), and four were studied through passage 11 (data
not shown). Levels of TGF- remained stable through
passage 8 and were similar to peripheral blood (PBL) and
P0 material; signiﬁcant decreases were noted after P8 for
those cells followed further out. HGF, galectin-1, IL-6, and
VEGF expression levels were signiﬁcantly higher in MSCs
as compared with PBL and marrow and remained rela-
tively stable through P5, with VEGF dropping off at P4,
HGF and galectin-1 dropping off at P7, and IL-6 dropping
off at P9. In contrast, IL-10 expression levels were ex-
tremely low, relative to control, in all passages. Variability
in expression levels was observed among different donors.
MSCs from four of these animals were also characterized
for cytogenetic stability at passages 0, 2, 6, and 11. Results
revealed normal karyotypes, without clonal numerical or
structural aberrations. The cells maintained clonal chro-
mosomal stability between passages 0 and 11 (Fig. 3).
Effect of MSCs on islet engraftment/function and
chimerism. Fig. 4A shows a schematic of the design used
to test the effect of intraportal islet/DBMC (group 1) and
intraportal islet/MSC (group 2) transplant on chimerism
and allogeneic islet engraftment. Islet function was de-
tected for all recipients, as evidenced by stabilization of
blood glucose levels, decreased exogenous insulin require-
ments, and positive fasting C-peptide. Attainment and
duration of insulin independence was associated with islet
dose (Tables 1 and 2).
Three animals in group 1 received intraportal islet/
DBMC cotransplants on POD 0 (Table 1) and intravenous
DBMCs on PODs 4 or 5 and 11. None of the group 1
animals experienced long-term graft survival, with all
recipients manifesting decreased graft function on PODs
21–25. Insulin independence was transiently observed for
the two monkeys that received a dose near the 10,000
IEQ/kg required for reproducible insulin independence in
this model. Donor-derived cells were only detected in
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FIG. 1. A: Phenotypic characterization of MSCs isolated from cynomolgus bone marrow. P0, aspirate; P1–P4, after ﬁrst, second, third, and fourth
trypsinization, respectively. Values represent mean  SD, number of different donors for each passage in parentheses. P0 (n  29); P1 (n  25);
P2 (n  24); P3 (n  14); and P4 (n  9). B: Representative ﬂow cytometric analysis of P2-cultured MSCs. Compared with isotype control (dashed
lines), cynomolgus bone marrow MSCs stained positive for CD105, MHC class I, CD29, and CD 73 and negative for CD45 and CD31. Histograms
represent consistent ﬁndings in 24 different donors. C: Adipogenic and osteogenic differentiation of MSCs (passage 2) isolated from cynomolgus
bone marrow aspirates. D: Effect of MSCs on PHA-induced stimulation of PBMC proliferation. Allogeneic MSCs signiﬁcantly inhibited PBMC
proliferation by 85% (P < 0.009); results for autologous cells were similar, but too few donors were tested to assess statistical signiﬁcance. CPM,
counts per minute. (A high-quality color representation of this ﬁgure is available in the online issue.)
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1–11).
Group 2 animals (Table 2) were treated with MSCs,
delivered both intraportally with the islets on POD 0 and
intravenously with the delayed DBMC infusions. All ani-
mals in group 2 received ﬁve million intraportal MSCs on
POD 0, but due to the broad range of IEQ transplanted,
this resulted in islet cell/MSC ratios from 3.7 to 13.4 (based
on an IEQ of 1,500 cells per islet). In contrast to group 1,
decreased graft function was not evident until POD 60
for group 2 (as compared with PODs 21–25 for group 1),
with ﬁve of eight animals C-peptide positive at necropsy.
Mean duration of function prior to destabilization was
81  20 days for group 2 versus 24  2 for group 1 (P 
0.001). This is illustrated in Fig. 4B, which shows fasting
blood glucose, exogenous insulin requirements, and fast-
ing C-peptide levels for one animal from group 1 (105-111;
11,598 IEQ/kg) and one animal from group 2 (35-493;
10,978 IEQ/kg) that received a comparable number of
islets. Extremely low levels of chimerism, not associated
with DBMC infusion, were observed transiently in three of
eight group 2 monkeys at 	1 month after transplant.
There was no signiﬁcant difference in the mean number
of islets transplanted in recipients from group 1 (9,774 
1,039 IEQ/kg; n  3) versus recipients from group 2
(7,412  1,359 IEQ/kg; n  8). However, we observed a
striking early increase in islet function in recipients of
intraportal islet/MSC cotransplants and chose three time
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FIG. 2. Gene expression levels for IL-6, IL-10, VEGF, TGF-, HGF, and galectin-1 for sequential passages from eight cynomolgus monkey donors.
All results were expressed as the log ratio of the copy number of the target gene to the copy number of 18S (used as the endogenous control gene).
Gene expression levels for PBL, P0, and P2–P5 were compared with levels expressed in P1 MSCs. n  8, *P < 0.05 versus P1.
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1 (intraportal islets/DBMC) and those in group 2 (intrapor-
tal islets/MSC): 3 days, 2 weeks, and 1 month posttrans-
plant. We ﬁrst determined that, within the eight animals in
group 2, there was no signiﬁcant difference in the fasting
C-peptide values between the ones treated with delayed
rapamycin and anti-CD154 (n  3) and those that began
treatment with rapamycin before transplant (n  5), or
between the animals that received PTH (n  6) and those
that did not (n  2), or between the animals that were
MHC class II mismatched (n  4) or haploidentical (n 
4), at any of the three time points (data not shown). All
eight animals in group 2 were therefore used for subse-
quent analysis. The results for the comparison of fasting
C-peptide levels at 3 days, 2 weeks, and 1 month posttrans-
plant between animals in group 1 and group 2 are shown in
Fig. 4C. Analysis of fasting C-peptide within each group as
a function of time showed a trend toward an increase in
function (P  0.07) over the ﬁrst posttransplant month
only in the animals that received intraportal islet/MSC.
Values for intraportal islet/DBMC recipients (group 1) did
not change signiﬁcantly in this same time frame. Compar-
ison of C-peptide values between the two groups at 1
month posttransplant showed a signiﬁcantly higher C-
peptide value (more than double) for recipients of islet/
MSC cotransplants (3.6  0.5 ng/ml vs. 1.4  0.4 ng/ml, P 
0.043; Fig. 4C).
Treatment of rejection with intravenous MSCs and
immunological changes in MSC-treated recipients.
We used donor and/or third-party MSCs to treat the
rejection process after intraportal islet/MSC transplant in
ﬁve of the animals in group 2 (93-108, 105-71, CW1H, 26-20,
105-131). Two animals received additional donor MSCs
(up to 2  10
6 MSCs/kg)  10 days after graft dysfunction
(93-108 received one dose and CW1H received two doses
administered 11 days apart), and one animal received a
single dose of MHC class II mismatched third party MSCs
(105-71) at the ﬁrst sign of rejection without success. Our
ﬁrst evidence of efﬁcacy in amelioration of rejection was
obtained for an animal that experienced a decrease in
function on POD 64 (animal 26-20, Table 2; Fig. 5). This
animal was treated with islet donor MSCs (2  10
6/kg,
MHC class II mismatched to the recipient) on PODs 64 and
68, but the exogenous insulin requirement (EIR) continued
to rise. Infusion of third-party MSCs (2  10
6 cells/kg,
MHC class II haploidentical to the recipient) on PODs 71,
77, 86, and 91 resulted in EIR reduction and increased
C-peptide, although the effect was short lived. Additional
third-party MSCs were given on PODs 155 and 160, and at
the time of necropsy, both fasting blood glucose and EIR
were decreasing.
Therapy of an additional recipient with islet donor
MSCs, haploidentical to the recipient, with greater dura-
tion of follow-up after MSC infusion, revealed clear rever-
sal of rejection (105-131, Table 2; Fig. 6). Fig. 6A–D
illustrates key points related to graft function, MSC infu-
sion, Tregs, and T-effector cells. This animal received a
very marginal mass of 3,000 IEQ/kg. Posttransplant, a
gradual reduction in insulin/kg was eventually offset by
increased insulin requirements and destabilization of
blood glucose on POD 94, accompanied by decreased
fasting C-peptide (Fig. 6A, lower panel). Additional islet
donor MSCs were given intravenously at 2  10
6/kg on
PODs 105, 110, 196, and 207. Of note is the gradual decline
in insulin requirement after MSC infusion on PODs 105 and
110 and the ultimate recovery of fasting C-peptide levels;
additional infusions were given on PODs 196 and 207 with
the rationale that repeated doses would have an additive
effect. Exogenous insulin requirements, fasting blood glu-
cose, and the day of additional MSC infusion (arrows) are
shown in Fig. 6A. Graft destabilization on POD 94 was
associated with increased CD3/8 effector cells and de-
creased FoxP3 Tregs (Fig. 6B). In addition, MSC infusion
after resolution of graft dysfunction resulted in an increase
in Tregs (Fig. 6B and C). Subsequent to graft recovery and
additional intravenous MSC infusion, Tregs increased in
percentage and absolute numbers to levels that were
higher than those observed before rejection. Results from
histological examination of tissues after necropsy are
shown in Fig. 6D. Examination of liver sections using
immunohistochemistry, as well as immunoﬂuorescence
staining, revealed insulin-positive, highly vascularized
scattered islets. Consistent with our previous observations
in STZ-induced diabetic monkeys, islets in the pancreas
were negative for insulin staining.
We measured the frequency of Tregs in ﬁve animals in
group 2. Representative data for two animals, shown in Fig. 6B
and C (105-131) and supplementary Fig. S1 (35-493), available
in an online appendix at http://diabetes.diabetesjournals.
org/cgi/content/full/db10-0136/DC1, illustrate that stable islet al-
lograft function was associated with an increased number of
Tregs in the periphery, while a decrease in Tregs occurred after
graft dysfunction.
DISCUSSION
The International Society for Cellular Therapy criteria for
human MSCs include ﬁbroblast-like morphology, adher-
ence to plastic, phenotypic characteristics, in vitro poten-
tial for trilineage differentiation, and inhibition of
proliferation of allo- or mitogen-activated lymphocytes
(39). Rhesus (40) and cynomolgus macaque (41) and
baboon (42) MSCs appear to be phenotypically and func-
tionally similar to their human counterparts. Our study
depicts the ﬁrst thorough characterization of cynomolgus
MSC phenotypic markers, gene expression levels, and
karyotype through several passages. Gene expression lev-
els for IL-6, IL-10, VEGF, TGF-, HGF, and galectin-1 vary
over several passages of MSCs from the same donor (as
well as between donors), indicating that the actual func-
P0  P2
P6  P11
FIG. 3. Trypsin-Giemsa banded karyotypes for MSCs from animal
105-74 from passages 0, 2, 6, and 11 showing a 42,XY normal male
Pearson classiﬁcation (52).
D.M. BERMAN AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 59, OCTOBER 2010 2563Group 1 (n=3)
Day - 6 -4 -3 -2 -1 0  3  5  10  11 14  18  28  49   monthly  
Thy + Flu       
Rapa          
IP islets + DBMC  
IV DBMC  
 
  
 
 
Group 2 (n=8)    
 
Day  -6 -4 -3 -2 -1 0 3 5 10 11 14 18 28 49 monthly
Thy +  Flu        
a 5C8                
b Daily PTH                    
c Rapa  
a Delayed Rapa         
IP islets + MSC  
IV DBMC + MSC  
  
  
POD
0 50 100 150 200
C
-
p
e
p
t
i
d
e
 
(
n
g
/
m
l
)
0
1
2
3
4
POD
0 50 100 150 200
C
-
p
e
p
t
i
d
e
 
(
n
g
/
m
l
)
0
1
2
3
4
POD
0 50 100 150 200
POD
0 50 100 150 200
E
I
R
 
(
I
U
/
k
g
/
d
a
y
)
0
1
2
3
4
5
E
I
R
 
(
I
U
/
k
g
/
d
a
y
)
0
1
2
3
4
5
F
a
s
t
i
n
g
 
B
l
o
o
d
 
G
l
u
c
o
s
e
 
(
m
g
/
d
l
)
0
100
200
300
400
F
a
s
t
i
n
g
 
B
l
o
o
d
 
G
l
u
c
o
s
e
 
(
m
g
/
d
l
)
0
100
200
300
400 insulin/kg/day
FBG
insulin/kg/day
FBG
Islets/DMBC Islets/MSC
A
B
C
3 days 2 weeks  1 month
C
-
p
e
p
t
i
d
e
 
(
n
g
/
m
l
)
0
1
2
3
4
5
MSC IP 
DBMC IP  *
FIG. 4. A: Schematic of the design used to test the effect of intraportal codelivery of islets with DBMCs (group 1) or with donor MSCs (group 2)
on chimerism and islet graft survival in two groups of animals. Animals in group 1 received induction therapy consisting of four doses of
thymoglobulin (Thy) and four doses of ﬂudarabine (Flu) on PODs 6, 4, 3, and 2. IM rapamycin (Rapa) was initiated on POD 2. Islets were
cotransplanted with DBMCs intraportally on POD 0, followed by intravenous (IV) infusions of DBMCs on PODs 5 and 11. Animals in group 2
received the same induction therapy with Thy and Flu.
aanti-CD154 (5C8) on PODs 1, 0, 3, 10, 18, 28, and monthly thereafter, and rapamycin
was initiated on POD 14 (n  3).
bPTH from POD 7o r6 until POD 49 (n  6).
cRapamycin was initiated on POD 1( n  5). B: EIR, fasting
blood glucose (FBG) (upper panel) and fasting C-peptide (lower panel) for representative animals from group 1 and group 2 that received similar
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between passages. These ﬁndings could impact clinical
outcomes and suggest a need for additional functional
criteria in the standardization of MSC products for cell
therapies.
The cytogenetic stability of these cells, studied up to
passage 11, appears to be in agreement with human
studies by Bernardo and colleagues (43), in which cells
from 10 human donors, followed to senescence or passage
25, showed no cytogenetic abnormalities or malignant
transformation. While small in numbers, our study dem-
onstrates the feasibility of using cynomolgus macaque
MSCs up to passage 11 for therapeutic efﬁcacy in future
studies.
MSCs have been shown to enhance DBMC engraftment
(17,18). Studies in rodent models suggest that an intrapor-
tal route of antigen delivery may be tolerogenic (44,45).
Despite intraportal infusion of MSCs or DBMCs with islets,
we did not observe enhancement of donor marrow en-
graftment, chimerism, or tolerance. We did observe signif-
icant enhancement of islet engraftment and function at 1
month posttransplant in recipients of intraportal MSCs as
compared with animals that received islets plus DBMCs.
To further deﬁne the signiﬁcance of the engraftment data
with MSCs, we compared 1-month posttransplant fasting
C-peptide values from the animals that received intrapor-
tal islet/MSC (3.6  0.5 ng/ml) versus two additional
historical, published groups. The ﬁrst group consisted of
three recipients of intraportal islets alone, treated with
thymoglobulin, ﬂudarabine, and rapamycin, plus sa-
marium lexidronam and delayed intravenous DBMCs on
PODs 5 and 11 (1.3  0.2 ng/ml) (46). The second group
comprised 19 recipients of intraportal islets alone under
the cover of steroid-free immune suppression (1.6  0.2
ng/ml) (38). Taken together, and including animals from
group 1 in the present study, it is striking that recipients of
islets/MSC had engraftment values of more than double
compared with 27 animals that did not get MSCs, regard-
less of the conditioning regimen (P  0.01). This suggests
that, compared to other regimens, MSCs provide a distinc-
tive advantage in promoting early islet engraftment. Mar-
row MSCs have been shown to express chemokine
receptors that mediate migration of these cells to pancre-
atic islets (20); after intracardiac infusion of MSCs in
diabetic mice, cells homed selectively to pancreatic islets
and glomeruli (21) and intravenous infusion of MSC was
accompanied by improved glycemic levels, reduced pan-
creatic insulitis, and pancreatic tissue regeneration (19,21–
23,25). Although this data may suggest that the mechanism
behind the engraftment effect of MSCs observed in our
NHP islet allograft model may involve migration of MSCs
to the pancreas and pancreatic islet regeneration, we did
not observe any insulin-positive islets in histological anal-
ysis of pancreas tissue after necropsy. We can hypothesize
that MSCs enhance islet engraftment by staying in prox-
imity to the islets at the time of cotransplant, providing
immunomodulatory, revascularization, and regenerative
signals. However, understanding the mechanism of action
of MSCs requires knowing where the MSCs localize after
intraportal or intravenous infusion. In an attempt to track
the fate of the implanted MSCs, we performed pilot
experiments in which each of two monkeys was trans-
planted with intraportal islets/green ﬂuorescent protein
(GFP)-tagged MSCs on POD 0 under the cover of anti-
CD154. One month posttransplant, the animals were killed
for histological examination of the tissues. Using immuno-
histochemistry, as well as measuring GFP DNA, we could
not ﬁnd any traces of the GFP-tagged MSCs in any of the
tissues of one of the animals, but we could detect some
numbers of islets. Both animals received induction therapy with thymoglobulin and ﬂudarabine in the week prior to transplant and IM rapamycin
starting on POD 1. The animal from group 1 (105-111, panel on the right) was transplanted with 11,598 IEQ/kg and 0.1  10
9 DBMC/kg from a
mismatched donor into the liver on POD 0, followed by intravenous DBMCs (0.33  10
9 cells/kg) on PODs 5 and 11. The animal from group 2
(35-493, panel on the left) was transplanted with 10,978 IEQ/kg and 1.4  10
6 MSCs/kg from a mismatched donor into the liver on POD 0, followed
by IV donor MSCs (5.8  10
6 cells/kg) together with CD11b depleted DBMCs (0.30  10
9 cells/kg) on PODs 5 and 11. C: Fasting C-peptide levels
for recipients of allogeneic islets in the liver at 3 days, 2 weeks, and 1 month posttransplant. Empty bars represent recipients of islet  MSC
codelivery in the liver and delayed IV DBMC  MSC infusion (n  8; group 2, Table 2). Black bars represent recipients of islet  DBMC codelivery
in the liver and delayed IV DBMC infusion (n  3; group 1, Table 1); *P  0.043 at 1 month posttransplant.
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FIG. 5. EIR and fasting blood glucose (FBG) (upper panel) and fasting
C-peptide (lower panel) for animal 26-20. This animal received induc-
tion therapy with thymoglobulin and ﬂudarabine in the week prior to
transplant, and IM rapamycin was initiated on POD 14 to achieve and
maintain trough levels of 15–20 ng/ml. In addition, treatment with
anti-CD154 (20 mg/kg) started on POD 1, with ﬁve doses in the ﬁrst
month posttransplant and monthly thereafter until POD 168. On POD
0, 3,928 IEQ/kg and 1.6  10
6 MSCs/kg from a mismatched donor were
transplanted into the liver. IV donor MSC (5.3  10
6 cells/kg), together
with CD11b depleted donor bone marrow cells (0.20  10
9 cells/kg)
were given on PODs 5 and 11. Additional donor MSCs (full arrow, 2 
10
6 cells/kg) were given on PODs 64 and 68, and third-party MSCs from
a haploidentical third party (dashed arrow, 2  10
6 cells/kg) were given
on PODs 71, 77, 86, 91,155, and 160.
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recipient (data not shown). Further experiments, includ-
ing tracking tagged MSCs after shorter periods posttrans-
plant, will be needed to elucidate the fate and potential
mechanisms of action for intraportally implanted MSCs in
our NHP model of islet transplantation.
Intraportal islet engraftment and stable function were
accompanied by an increase in the percentage of Tregs in
the circulation. The immunomodulatory effect of MSCs
has been shown to involve generation of Tregs in in vitro
studies (47,48), as well as in the prevention of autoimmune
diabetes in NOD mice (26); however, our data are the ﬁrst
evidence of in vivo Treg generation in the context of
MSC-augmented allogeneic islet grafts in a preclinical
model with close proximity to humans.
To the best of our knowledge, this is the ﬁrst time that
intravenous infusion of either islet donor or third-party
marrow MSCs were used to reverse episodes of islet graft
rejection in the context of allogeneic islet transplantation.
The most striking result was obtained after intravenous
infusion of two doses of 2  10
6 islet donor MSC/kg
spaced 4 days apart, given after the EIR had reached levels
similar to those previous to transplantation of a marginal
islet mass. The resolution of graft dysfunction was accom-
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FIG. 6. A: EIR and fasting blood glucose (FBG) (left panel) and fasting C-peptide (right panel) for animal 105-131. This animal received induction
therapy with thymoglobulin and ﬂudarabine in the week prior to transplant, and IM rapamycin was initiated on POD 14 to achieve and maintain
trough levels of 15–20 ng/ml. In addition, treatment with anti-CD154 (20 mg/kg) started on POD 1, with ﬁve doses in the ﬁrst month
posttransplant and monthly thereafter. On POD 0, 3,000 IEQ/kg and 1.0  10
6 MSCs/kg from a haploidentical donor were transplanted into the
liver. IV donor MSCs (3.4  10
6 cells/kg), together with CD11b depleted DBMCs (0.17  10
9 cells/kg) were given on PODs 5 and 11. Additional
donor MSCs (full arrow, 2  10
6 cells/kg) were given on PODs 105, 110, 196, and 207. B: EIR (line), % CD4/25 bright FoxP3 T-cells (ﬁlled circles),
and %CD3/8 positive T-cells (empty circles) for animal 105-131. Arrows indicate donor MSCs (2  10
6 cells/kg) given on PODs 105, 110, 196, and
207. C: Frequency of FoxP3 positive T-cells in peripheral blood of animal 105-131 gated for CD3
CD4
CD25
bright lymphocytes. D: Histopathology
of liver sections after necropsy. Left panel shows immunohistochemistry staining of an islet with hematoxylin and eosin and positive signal for
insulin (brown) (200). Right panel shows a representative confocal microscopy analysis with immunoﬂuorescence for insulin (red), glucagon
(blue), and blood vessels (green) (400). (A high-quality digital representation of this ﬁgure is available in the online issue.)
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appeared to be an important factor because MSCs given
several days after graft destabilization were ineffective.
These ﬁndings suggest that the inﬂammatory process
during rejection may provide activating cytokines or che-
mokines that enhance efﬁcacy of MSC suppression. In
another in vivo model of T-cell-mediated tissue destruc-
tion, IFN- was critical for suppression of graft versus host
disease by MSCs (49).
The use of a histocompatibility matched, autologous, or
a mismatched source of MSCs when treating autoimmune
disorders is still in debate. Fiorina et al. (24) reported
delayed onset of diabetes as well as reversal of hypergly-
cemia in NOD mice treated with allogeneic but not autol-
ogous MSCs, while Solari et al. (27) observed prolonged
survival of allogeneic islets in STZ-induced diabetic rats
with autologous but not with allogeneic MSCs. The immu-
nogenicity and functional integrity of MSCs from subjects
with autoimmune diseases is also not clear. Transplanta-
tion of autologous MSCs in NOD mice was accompanied
by development of soft tissue and visceral tumors, which
were not observed with the transfer of allogeneic MSCs
(24). A concern with MSCs from patients with autoim-
mune disease has been the potential for decreased immu-
nomodulatory capacity, although recent studies reported
that MSCs from patients with multiple sclerosis and rheu-
matoid arthritis had normal cell surface and molecular
phenotype and ability to support hematopoiesis (50,51). It
is not clear whether the capacity of these MSCs is as
robust as allogeneic MSCs for immunomodulation or
whether these cells require additional manipulation ex
vivo to augment their immunomodulatory capacity. Our
results, obtained in a preclinical model, justify the clinical
investigation of MSC as both a feasible approach for
enhancement of islet engraftment and as a safe and
effective antirejection therapy.
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